ZYDUS WELLNESS LTD.-$ - 531335 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate / issue of duplicate share certificate under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations) ZYDUS WELLNESS LTD.-$ - 531335 - Closure of Trading Window
Pursuant to the Code of Insider Trading of the Company, we hereby inform that our trading window shall remain closed from January 1, 2023 till 48 hours after the declaration of unaudited financial results for the quarter and nine months ending on December 31, 2022 for the Directors and Designated Persons and their immediate relatives, for trading in the equity shares of the Company. The date of board meeting for approving the unaudited financial results for the quarter and nine months ending on December 31, 2022 will be intimated in due course of time. ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper cutting dated December 22, 2022 with regard to notice to the shareholders for transfer of shares to the Investor Education and Protection Fund ('IEPF').
Nepal bans import of medicines from 16 Indian companies, including Patanjali's Divya Pharmacy, Zydus
The move comes after the WHO issued an alert on Indian-made cough syrups, which were allegedly responsible for the deaths of children in Gambia.
Zydus gets USFDA nod for two generic drugs
The company has also received final approval from the US Food and Drug Administration (USFDA) to market Pregabalin capsules in multiple strengths, the Ahmedabad-based drug maker said in a statement.
Zydus gets final USFDA nod to market epilepsy and menopause drugs
With a market valuation of 41,515.55 Cr, Zydus Lifesciences Ltd. is a large cap business that operates in the pharmaceutical industry.
Zydus gets USFDA nod to market generic epilepsy drug
The company said it has received the final approval from the US Food and Drug Administration (USFDA) to market the product in multiple strengths. Zydus Lifesciences gets USFDA nod for thyroid hormone deficiency drug
The company's US-based unit has received tentative approval from the US Food and Drug Administration (USFDA) to market the medication, the drug firm said in a regulatory filing. ZYDUS WELLNESS LTD.-$ - 531335 - Submission Of Half Yearly Disclosure On Related Party Transactions
Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, please find enclosed the details of Related Party Transactions for the half year ended September 30, 2022 in the format prescribed by SEBI.
Hold Zydus Lifesciences; target of Rs 480: ICICI Direct
ICICI Direct recommended hold rating on Zydus Lifesciences with a target price of Rs 480 in its research report dated November 14, 2022.